Nektar Therapeutics stock: HC Wainwright lifts FY2026 outlook
Published on 11/20/2026 at 22:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst outlook and development plans
- HC Wainwright raised its fiscal 2026 EPS estimate while retaining a Buy rating and a USD 185 target.
- Nektar is advancing rezpegaldesleukin through Phase 3 studies, with initial data expected in summer 2028.
- Third-quarter revenue declined year over year, while cash and investments reached USD 952.9 million at September 30.
HC Wainwright raised its fiscal 2026 earnings estimate for Nektar Therapeutics after a research report issued on Monday, November 16, according to MarketBeat. The analyst now expects a fiscal 2026 loss of USD 7.06 per share, compared with a previous estimate of USD 7.49, while maintaining a Buy rating and a USD 185 price target.
Nektar Therapeutics stock traded at 27.61 euros on Lang & Schwarz at 10:14 p.m. CET on Friday, November 20, 2026.
Analyst outlook and development plans
HC Wainwright projects further losses through 2029 and a return to positive earnings of USD 0.59 per share in 2030. The estimate change comes as Nektar advances rezpegaldesleukin, also known as REZPEG or NKTR-358, in late-stage studies for autoimmune and inflammatory diseases.
Nektar said in its November 12 third-quarter release that all three global ZENITH registrational studies in atopic dermatitis had started. The company also said its global ZENITH study in alopecia areata was on track to begin in December, with initial data readouts expected in summer 2028.
Quarterly results and cash position
For the quarter ended September 30, Nektar reported revenue of USD 9.4 million, down from USD 11.8 million a year earlier. Net loss was USD 55.7 million, or USD 1.63 per share, compared with a net loss of USD 35.5 million, or USD 1.87 per share, in the prior-year quarter.
Cash and investments in marketable securities totaled USD 952.9 million at September 30, compared with USD 245.8 million at December 31, 2025. The balance supports the company's clinical development plans as it works toward later-stage trial milestones.
The Nasdaq Composite provides the broader U.S. market setting for Nasdaq-listed biotechnology shares.
More news and analyses on Nektar Therapeutics stock
Nektar Therapeutics
- ISIN: US6402683063
- Ticker: NKTR
- Home exchange: Nasdaq
- Lang & Schwarz quote: 27.61 euros on November 20, 2026, at 10:14 p.m. CET
